//]]>

Cancer Immunotherapy (Record no. 17564)

000 -LEADER
fixed length control field 03649nam a22004095i 4500
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140310150237.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 121116s2013 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781461447320
978-1-4614-4732-0
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC261-271
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 614.5999
Edition number 23
264 #1 -
-- New York, NY :
-- Springer New York :
-- Imprint: Springer,
-- 2013.
912 ## -
-- ZDB-2-SBL
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Curiel, Tyler J.
Relator term editor.
245 10 - IMMEDIATE SOURCE OF ACQUISITION NOTE
Title Cancer Immunotherapy
Medium [electronic resource] :
Remainder of title Paradigms, Practice and Promise /
Statement of responsibility, etc edited by Tyler J. Curiel.
300 ## - PHYSICAL DESCRIPTION
Extent IX, 483 p. 19 illus., 16 illus. in color.
Other physical details online resource.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Introduction -- Historical Perspectives and Current Trends in Cancer Immunotherapy -- T cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment -- Adoptive T Cell Transfer -- Dendritic Cell-Based Cancer Immunotherapy: Achievements and novel concepts -- Peptide and Protein-based Cancer Vaccines -- Antigen Targeting to Dendritic Cells for Cancer Immunotherapy -- Cytokines in the Treatment of Cancer -- Immune Co-signaling to Treat Cance -- Managing Regulatory T cells -- Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and therapeutic perspectives -- Antibodies as Cancer Immunotherapy -- Targeted Toxins in Cancer Immunotherapy -- Miscellaneous Approaches and Considerations: TLR agonists and other inflammatory agents, anti-chemokine agents, infectious agents, tumor stroma targeting, age and sex effects, and miscellaneous small molecules -- Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies -- Monitoring Antigen-Specific Responses in Clinical Trials of Immunotherapy -- Index.
520 ## - SUMMARY, ETC.
Summary, etc This volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical trials are also discussed, as are key pre-clinical developments. The major challenges and intellectual issues facing investigators developing novel immunotherapeutics are discussed in detail as are conceptual developments influencing current and future treatment strategies. Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy. Although the field is evolving rapidly, we have taken pains to ensure that information was as up to date as possible as the text went to press.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
Topical term or geographic name as entry element Oncology.
Topical term or geographic name as entry element Toxicology.
Topical term or geographic name as entry element Biomedicine.
Topical term or geographic name as entry element Cancer Research.
Topical term or geographic name as entry element Pharmacology/Toxicology.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9781461447313
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-1-4614-4732-0
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme
Item type E-Book
Copies
Price effective from Permanent location Date last seen Not for loan Date acquired Source of classification or shelving scheme Koha item type Damaged status Lost status Withdrawn status Current location Full call number
2014-04-04AUM Main Library2014-04-04 2014-04-04 E-Book   AUM Main Library614.5999

Languages: 
English |
العربية